EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Challenges in Conducting Quantitative Patient-Centered Benefit-Risk Assessments: A Case Study in Ph + ALL with Immature Efficacy Data

Ajibade Ashaye, Caitlin Thomas, Vamsi Kota, Nicolas Krucien, Kevin Marsh

Therapeutic Innovation & Regulatory Science · 2026-05 · 60 (3) · 617-628

DOI: 10.1007/s43441-026-00935-x ↗

Kurz gefasst

Fachartikel in der Zeitschrift Therapeutic Innovation & Regulatory Science, online erschienen am 09.03.2026. Verfasst von Ajibade Ashaye und 4 weiteren Autor:innen. Beteiligte Einrichtung: Takeda Development Center Americas, Inc., 500 Kendall Street, Cambridge, MA, 02142, USA. ajibade.ashaye@takeda.com. Hauptthemen laut MEDLINE: Precursor Cell Lymphoblastic Leukemia-Lymphoma, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Takeda Development Center Americas Inc..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Quantitative benefit-risk assessment (qBRA) can reveal how patients balance benefits and risks of cancer treatments. To align with qBRA good practice guidelines, researchers must address challenges including attribute value dependence, double counting, attribute dominance, and uncertainty associated with immature clinical trial outcomes. We present a case study illustrating these challenges in a qBRA of treatment preferences among patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Preferences were elicited using a discrete choice experiment (DCE). First, we explain how we mitigated potential dominance of survival outcomes by narrowing the range of overall survival (OS) durations that each participant considered. Second, we describe how we acknowledged the conceptual interaction between OS and duration of remission (DOR) attributes and tested for a statistical interaction. Third, we detail how we conducted qBRA with uncertain efficacy data using bivariate sensitivity analysis. Bivariate sensitivity analysis based on DCE-elicited preferences and head-to-head clinical performance data showed that if the considered treatments – ponatinib + chemotherapy and imatinib + chemotherapy – had equivalent efficacy, 52.9% (95% CI: 52.5%–53.4%) of DCE participants would be expected to choose ponatinib over imatinib. If ponatinib offered 10-month longer DOR and 20-month longer OS vs. imatinib, 71.6% (95% CI: 67.2%–76.0%) would choose ponatinib. Probabilistic sensitivity analyses showed that the probability of ≥ 70% of patients preferring ponatinib is 77.5% if ponatinib offers 15-month longer OS and DOR and 93.0% if it offers 45-month longer OS and DOR. Preference heterogeneity analyses identified that the overall choice probability results hold for all subgroups in nearly all scenarios.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Precursor Cell Lymphoblastic Leukemia-LymphomaAntineoplastic Combined Chemotherapy ProtocolsHumansRisk AssessmentFemaleImidazolesImatinib MesylatePhiladelphia ChromosomeMalePatient PreferenceTreatment OutcomeAdultMiddle AgedPyridazines

Stichwörter der Autor:innen

Benefit-risk assessmentDiscrete choice experimentLeukemia, lymphoblastic, acute, philadelphia-positivePatient preferencePatient-centered outcomes research

Substanzen

ImidazolesImatinib MesylateponatinibPyridazines

Autor:innen und Institutionen

  • Takeda Development Center Americas, Inc., 500 Kendall Street, Cambridge, MA, 02142, USA. ajibade.ashaye@takeda.com.
  • PPD Evidera Patient-Centered Research, Thermo Fisher Scientific, London, UK.
  • Section of Hematology & Oncology, Georgia Cancer Center at Augusta University, Augusta, GA, USA.

Förderung

  • Takeda Development Center Americas Inc.

Zitieren

APA

Ashaye, A., Thomas, C., Kota, V., Krucien, N., & Marsh, K. (2026). Challenges in Conducting Quantitative Patient-Centered Benefit-Risk Assessments: A Case Study in Ph + ALL with Immature Efficacy Data. Therapeutic Innovation & Regulatory Science, 60(3), 617-628. https://doi.org/10.1007/s43441-026-00935-x

Vancouver

Ashaye A, Thomas C, Kota V, Krucien N, Marsh K. Challenges in Conducting Quantitative Patient-Centered Benefit-Risk Assessments: A Case Study in Ph + ALL with Immature Efficacy Data. Therapeutic Innovation & Regulatory Science. 2026;60(3):617-628. doi:10.1007/s43441-026-00935-x

BibTeX
@article{Ashaye2026,
  author = {Ashaye, Ajibade and Thomas, Caitlin and Kota, Vamsi and Krucien, Nicolas and Marsh, Kevin},
  title = {Challenges in Conducting Quantitative Patient-Centered Benefit-Risk Assessments: A Case Study in Ph + ALL with Immature Efficacy Data},
  journal = {Therapeutic Innovation & Regulatory Science},
  year = {2026},
  volume = {60},
  number = {3},
  pages = {617--628},
  doi = {10.1007/s43441-026-00935-x}
}
Kostenlos starten →